The Unlikely Rise of Alan: Why a Health Insurance Startup is Defying the Unicorn Bust
In a tech landscape littered with the carcasses of overvalued startups, Alan’s €5 billion valuation feels like a mirage in a desert of downturns. While 30% of European unicorns are reportedly losing their billion-dollar horns, this French health insurance upstart is not just surviving—it’s thriving. But what makes Alan’s story so compelling isn’t just its financial success; it’s the why behind it.
From Niche to Necessity: The Healthtech Pivot That Paid Off
Alan’s journey from a 2016 startup to a €5 billion behemoth is a masterclass in timing and execution. What started as a digital health insurance platform for freelancers and small businesses has evolved into a full-fledged ecosystem serving one million users. But here’s the kicker: Alan didn’t just digitize insurance—it humanized it.
Personally, I think this is where Alan’s genius lies. Health insurance is notoriously impersonal, but Alan’s app-based approach—allowing users to manage reimbursements, access doctors, and track health habits—turns a bureaucratic nightmare into a user-friendly experience. What many people don’t realize is that this shift isn’t just about convenience; it’s about trust. In an industry where trust is currency, Alan’s focus on transparency and accessibility has been a game-changer.
The AI Angle: A Bold Bet or a Necessary Evolution?
Alan’s CEO, Jean-Charles Samuelian-Werve, recently hinted at ambitious investments in tech and AI. This isn’t just corporate jargon—it’s a strategic pivot. With his ties to Mistral AI, Samuelian-Werve is positioning Alan at the intersection of healthcare and artificial intelligence. But here’s the question: Is this a moonshot or a necessity?
From my perspective, AI in healthcare is no longer optional—it’s inevitable. Whether it’s predictive analytics, personalized care, or streamlining operations, AI is the future. Alan’s early move into this space could give it a competitive edge, but it’s also a risky bet. What this really suggests is that Alan isn’t just playing the game; it’s rewriting the rules.
Global Ambitions, Local Challenges: The Expansion Paradox
Alan’s international expansion—from Belgium and Spain to Canada—is impressive, but it’s not without hurdles. The company claims it’s approaching operating break-even, but its focus on growth over profitability raises eyebrows. With net losses halved in the past year, investors seem willing to play the long game. But for how long?
One thing that immediately stands out is the cultural and regulatory challenges of expanding into new markets. Health insurance isn’t a one-size-fits-all product; it’s deeply rooted in local contexts. Alan’s ability to adapt its model to diverse markets will be the ultimate test of its scalability. If you take a step back and think about it, this isn’t just about growth—it’s about survival in a fragmented global market.
The Investor Confidence Factor: Why Alan is the Exception
Alan’s latest funding round, led by Index Ventures and joined by high-profile names like Shopify’s Tobi Lütke and footballer Antoine Griezmann, is a vote of confidence in its vision. But what makes investors so bullish on a health insurance startup in a bearish market?
In my opinion, it’s Alan’s ability to combine innovation with pragmatism. Unlike many tech unicorns that chased hype, Alan focused on solving a real problem—healthcare accessibility—with a sustainable business model. Its €785 million in annual recurring revenue in 2025 isn’t just a number; it’s proof that its approach works. What many people don’t realize is that in a post-pandemic world, healthcare isn’t just a service—it’s a priority.
The Broader Implications: What Alan’s Success Tells Us About the Future
Alan’s story isn’t just about a startup beating the odds; it’s a reflection of larger trends. The convergence of tech and healthcare, the rise of digital-first services, and the growing demand for personalized care are reshaping industries. But here’s the deeper question: Can Alan’s model be replicated, or is it a once-in-a-decade anomaly?
A detail that I find especially interesting is how Alan’s success challenges the narrative of tech startups as disruptors. Instead of upending the industry, Alan is collaborating with traditional players, like Belgian bank Belfius, to create a hybrid model. This raises a deeper question: Is the future of innovation about disruption or integration?
Final Thoughts: Alan’s Valuation is Just the Beginning
Alan’s €5 billion valuation is a milestone, but it’s not the endgame. The company’s focus on AI, international expansion, and operational efficiency suggests it’s just getting started. But as it grows, it will face new challenges—regulatory scrutiny, competitive pressures, and the ever-present risk of overreaching.
Personally, I think Alan’s biggest test will be staying true to its mission while scaling. In a world where tech companies often lose sight of their purpose, Alan’s commitment to making healthcare more accessible and human could be its greatest asset. If you take a step back and think about it, Alan isn’t just building a company—it’s building a movement. And that, in my opinion, is worth far more than €5 billion.
